Sotera Health Co Aktie News

Sotera Health Company (SHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

CLEVELAND, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, is presenting today at the 44th Annual J.P. Morgan Healthcare Conference.

9,720,000 shares were sold indirectly for a transaction value of ~$158.7 million on Dec. 3, 2025. The sale represented 22.18% of total indirect holdings, reducing indirect exposure from 43,822,952 to 34,102,952 shares.

CLEVELAND, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 1:30 p.m.

Sotera Health provides sterilization and lab testing services for the health care industry.

CLEVELAND, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 30,000,000 shares of its common stock, par value $0.01 per share. All 30,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders.

Sotera Health Company ( SHC ) Q3 2025 Earnings Call November 4, 2025 9:00 AM EST Company Participants Jason Peterson - VP & Treasurer Michael Petras - Chairman & CEO Jonathan Lyons - Senior VP & CFO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Luke Sergott - Barclays Bank PLC, Research Division David Windley - Jefferies LLC, Research Division Brett Fishbin -...

Q3 2025 net revenues increased  9.1% to $311 million , or 8.0% on a constant currency basis ( 1) , compared to Q3 2024 Q3 2025 net income of $48 million, or $0.17 per diluted share, compared to net income of $17 million or $0.06 per diluted share in Q3 2024 Q3 2025 Adjusted EBITDA ( 1 ) increased 12.2% to $164 million, or 11.2% on a constant currency basis, compared to Q3 2024 Q3 2025 Adjusted ...